If partial dissolution is not seen by nine to 12 months, the likelihood of success of treating loner is greatly reduced; Chenodiol should be discontinued if there is no response by 18 months. Safety of use beyond 24 months is not established.
Stone recurrence can be expected within five years in 50% of cases. After confirmed dissolution, treatment generally should be stopped. Serial cholecystograms or ultrasonograms are recommended to monitor for recurrence, keeping in mind that radiolucency and gallbladder function should be established before starting another course of Chenodiol. A prophylactic doses is not established; reduced doses cannot be recommended; stones have recurred on 500 mg/day. Low cholesterol or carbohydrate diets, and dietary bran, have been reported to reduce biliary cholesterol; maintenance of reduced weight is recommended to forestall stone recurrence.
HOW SUPPLIED
Chenodal® (chenodiol tablets) is available as white film-coated 250 mg tablets imprinted “MP” on one side and "250" on the other in bottles of 100, NDC 68974-876-40.
Store at 20oC to 25oC (68oF to 77oF) [see USP Controlled Room Temperature].
Dispense in a tight container.
Manufactured for:
Retrophin, Inc.
San Diego, CA 92130
866-758-7068
Rev. 06/15
PRINCIPAL DISPLAY PANEL
NDC 68974-876-40
Chenodal
250 mg
100 Tablets
Rx Only |
